Abstract
Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML). However, whether it should he discontinued in patients who achieve sustained molecular response is debated. We describe 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued. Two patients relapsed after 7 and 10 months and promptly responded after restarting therapy; 2 patients are off therapy at the last follow-up visit after 14 and 15 months and are still in complete molecular remission.
Original language | English |
---|---|
Pages (from-to) | 979-981 |
Number of pages | 3 |
Journal | Haematologica |
Volume | 90 |
Issue number | 7 |
Publication status | Published - Jul 2005 |
Keywords
- Chronic myeloid leukemia
- Imatinib
- Therapy discontinuation
ASJC Scopus subject areas
- Hematology